The Diagnostic Imaging CT modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of CT across the healthcare continuum, from various cancer screenings, such as lung and colon, to cardiothoracic imaging, to appendicitis, and more.

Latest News

Computed Tomography Study Finds Nearly 44 Percent of Interstitial Lung Abnormalities Are Not Reported
Computed Tomography Study Finds Nearly 44 Percent of Interstitial Lung Abnormalities Are Not Reported

November 20th 2024

While a large retrospective study found that interstitial lung abnormalities (ILAs) were evident on 1.7 percent of computed tomography (CT) scans, researchers found that 43.9 percent of ILAs, including fibrotic ILAs, were not reported.

Meta-Analysis Assesses Prognostic Role of CT-Based Coronary Artery Calcification in Patients with Lung Cancer
Meta-Analysis Assesses Prognostic Role of CT-Based Coronary Artery Calcification in Patients with Lung Cancer

November 19th 2024

New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging

November 18th 2024

Photon-Counting CTA for Patients with PAD: What the Research Reveals About Assessment for Stenotic Lesions
Photon-Counting CTA for Patients with PAD: What the Research Reveals About Assessment for Stenotic Lesions

November 14th 2024

Spectral CT System Gets FDA Clearance for Radiation Oncology Use
Spectral CT System Gets FDA Clearance for Radiation Oncology Use

November 12th 2024

Latest CME Events & Activities

19th Annual New York Lung Cancers Symposium®

November 16, 2024

Register Now!

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?

View More

Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC

View More

Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings

View More

School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio

View More

Annual Hawaii Cancer Conference

January 25-26, 2025

Register Now!

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®

View More

Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?

View More

Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

2025 International Symposium of Gastrointestinal Oncology (ISGIO)

September 12-13, 2025

Register Now!

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

View More

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

View More

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

View More

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

View More

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

View More

© 2024 MJH Life Sciences

All rights reserved.